Microfluidic technologies for advanced antimicrobial susceptibility testing.

Area of Science:

• Biomedical Engineering
• Infectious Diseases
• Clinical Diagnostics

Background:

• Antimicrobial resistance (AMR) poses a significant global public health threat, exacerbated by the improper use of antibiotics.
• Current clinical diagnostic methods for bacterial infections and antimicrobial susceptibility testing (AST) are slow and labor-intensive, often necessitating empirical treatment.
• The need for rapid, accurate diagnostic tools is critical to guide evidence-based antimicrobial therapy and combat AMR.

Purpose of the Study:

• To review recent advancements in microfluidic assays for the rapid identification of bacterial pathogens.
• To summarize the development of microfluidic platforms for expedited antimicrobial susceptibility testing (AST).
• To discuss the potential of microfluidic-based AST in advancing next-generation infection diagnosis.

Main Methods:

• Review of recent scientific literature on microfluidic technologies applied to bacterial diagnostics and AST.
• Analysis of different microfluidic assay designs and their performance metrics.
• Discussion of the integration of microfluidics with other technologies for enhanced diagnostic capabilities.

Main Results:

• Microfluidic devices enable faster pathogen identification compared to traditional methods.
• Emerging microfluidic assays significantly reduce the time required for AST.
• These technologies show promise for point-of-care diagnostics and personalized medicine.

Conclusions:

• Microfluidics represents a transformative approach to infection diagnosis and AST.
• Rapid and accurate diagnostics powered by microfluidics are essential for effective antimicrobial stewardship.
• Further development of microfluidic-AST platforms is crucial for combating the rising threat of antimicrobial resistance.